What is capisetinib/caposetinib used to treat?

Capivasertib is a small molecule kinase inhibitor that specifically targets the AKT signaling pathway and blocks the proliferation and survival signals of cancer cells. Its clinical application is mainly used in patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer, especially those with locally advanced or metastatic breast cancer associated with gene changes such as PIK3CA, AKT1 or PTEN. These genetic changes often lead to tumor cell resistance to standard endocrine therapy, so precise intervention through drugs targeting the AKT pathway is needed.

In actual clinical applications, carpisetin is usually used in combination with fulvestrant to enhance the therapeutic effect. The combination regimen is particularly suitable for patients whose disease has progressed after at least one endocrine-based therapy in the metastatic setting, or who have relapsed within 12 months of completing adjuvant endocrine therapy. By interfering with the AKT signaling pathway, carpisetin can inhibit tumor growth, slow down disease progression, and improve patients' sensitivity to endocrine therapy.

The mechanism of carpisetin is different from traditional chemotherapy. It is a targeted drug that does not rely on broad-spectrum cytotoxicity, so it has advantages in reducing systemic toxicity. Treatment is usually administered orally to patients, allowing for long-term maintenance treatment in an outpatient or home setting. Used in combination with fulvestrant, the drug's inhibitory effect on tumors can be further enhanced and personalized precision treatment can be achieved.

In addition, capisetig has shown significant efficacy in patients with specific gene alterations in clinical studies and real-world data, providing new ideas for the treatment of HR-positive and HER2-negative breast cancer. With the popularization of domestic genetic testing technology, more patients can accurately identify related mutations such as PIK3CA, AKT1 or PTEN, thus benefiting from the precise treatment plan of carpisetin.

Reference materials:https://www.drugs.com/mtm/capivasertib.html